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Meta-analysis of the long-term effects of inhaled corticosteroids in chronic 
obstructive pulmonary disease (COPD)
P.M. van Grunsven, C.P. van Schayck, J.P. Derenne1, H.A.M. Kerstjens2,
T.E.J. Renkema2, D,S. Postma2, T. Simüovvski1, R .P Akkermans,
P.C.M. Pasker-de Jong1, P.N.R. Dekhuijzen4, CJL.A.. van Herwaarden 4, C. van 
Weel. Dept, o f General Practice and Social Medicine, University o f Nijmegen,
The Netherlands:, 3 Dept, o f  Epidemiology, University o f Nijmegen, The 
Netherlands, *Dept. o f Pulmonology, University o f Nijmegen, The Netherlands,
2Dept, o f Pulmonology, University o f  Grtmingeti, The Netherlands, lDept. of 
Pulmonology, Hospital Pitié-Salpêtrière, Paris, France
The roie of inhaled corticosteroids (ICS) in the long-term management of COPD 
is still unclear. Therefore, we performed a meta-analysis of the three two-year 
studies published on this subject (Kerstjens et al: N Engl J Med 1992; 327: 
1413-9, Derenne et al: Am J Respir Crit Care 1995; 151: A463, Renkema ct 
al: Chest 1996; 109; 1156-62. Patients with “asthmatic features” were excluded 
by analyzing the original data, The effect on FEVi was assessed by a multiple 
repeated measurement technique in which time and drug effects were investigated. 
95 (of the original number of 140) Patients treated with ICS (81 with 1500 p,g 
beclomethasone, 6 with 1600 fig  budesonide, and 8 with 800 /¿g beclomethasone) 
were included. 88 Patients treated with placebo were included (of the initially 144 
patients). No baseline differences were observed (mean age 61 years, mean FEVj 
= 45%pred,)> Worsening of the disease was the drop-out reason in 4 patients of 
the ICS group vs. 9 of the placebo group (p = 0,11). The estimated two-year 
difference in the prebronchodilator FEVj was +0.090L (95% confidence interval 
(c.i.) +0.010L to +0.170L) in the ICS group versus placebo, the postbronchodilator 
FEVi showed a difference of +0.083L (95% c.i, +0.003L to +0.163L). In conclu­
sion, this meta-analysis showed beneficial long-term effects of ICS on the FEVi 
in patients with a clear diagnosis of COPD.
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When to perform  arterial blood gases (ABG) in stable chronic obstructive 
pulmonary disease (COPD)?
N. Roche, B. Herer, T.C. Chinet, S. Labrunc, G.J. Huchon. Université de Paris 
René Descartes, Service de Pneumologie* Hôpital Ambroise Paré, F-92104 
Boulogne, France
In patients with stable COPD, there is no agreement on the FEY \ threshold above 
which ABG are unnecessary to identify patients who would require supplemental 
O2 therapy. The American Thoracic Society and French guidelines recommend 
to perform ABG when FEV] is less than 50% predicted, whereas the European 
Respiratory Society recommend to perform ABG when FEVi is less than 70% 
predicted. Several studies have shown a poor correlation between spirometry and 
Pa02- We studied data from 60 stable COPD patients to determine the baseline 
FEVj threshold above which patients exhibit no severe hypoxemia (as defined by 
PaÛ2 <60 mmHg). Spirometry and ABG were performed on the same day in each 
patient, at least three weeks after the last exacerbation.
There was a weak but significant correlation between FEVj and Pa02 (r2 -  0.13, 
p = 0.005), The correlation between FEVI and PaC02 was stronger (r2 = 0.25, 
p = 0,00005), In all patients whose FEVj was >55% predicted, Pa02 was >60 
mmHg
These data suggest that 55% would be an acceptable FEVj threshold above which 
measurement of ABG are not necessary in stable COPD patients,
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Survey of prescription of long term  oxygen therapy outside guidelines
A, Taytard, D, Veale, E. Chailleux, J.C, Cardinaud. Groupe d ‘Etude Observatoire 
CMTS, ANTADIR, Bid St Michel, 75006 Paris, France
Guidelines for the prescription of long term oxygen therapy (LTOT) have been 
published but many surveys have found a large proportion of patients prescribed 
LTOT to have arterial oxygen pressure above guideline thresholds. We have sur­
veyed prescribes of LTOT to patients enrolled in the ANTADIR (French National 
Respiratory homecare network) Observatory, 2081 questionnaires were sent to 
prescribes identified by 20 regional associations asking if they ever prescribed 
LTOT to stable COPD patients with Pa02 >  60 mmHg and asking them to mark 
any of 9 suggested situations or “other reason” for such prescription. 654 replies
have been received. The mean age of doctors was 43.5 ±  7 yr. and 81% were 
respiratory physicians. 117/654 (17.88%) had never prescribed LTOT at Pa02 > 
60 mmHg. The remaining 537 marked a median of three options. 154 marked 5 
options or more. The commonest motives for prescription outside guidelines were 
“nocturnal desaturation” (386), “pulmonary hypertension” (331), and “recurrent 
clinical right heart failure” (314). 172 (31%) doctors ticked at least these three 
situations together. In contrast the options of prescription “in response to demand 
by the patient” or “family” were only chosen 40 times. 309 prescribed for “effort 
desaturation” , 215 for dyspnea", 139 for "repeat hospitalization“, 127 for ’’poly- 
cythaemia". We conclude that physicians prescribe LTOT outside guidelines for 
objective rather than subjective reasons of perceived severity of disease and trials 
of efficacy of LTOT in these circumstances are required.
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Nocturnal oxyhemoglobin desaturation (NOD) as predictor of long-term 
oxygen therapy (LTOT)
M. Rizzi, A. Bellonel , M. Greco, A. Andreoli, M. Bamberga, M. Sergi. Servizio 
di Fisiopatologin Respiratoria Ospedale L  Sacco-Milano; [Se)vizio di 
Fisiopatologia Respiratoria e Bmncopneumologia Ospedale Rho-Passirana, Italy
NOD often occurs among COPD patients with daytime Pa02 < 60 mmHg, and 
our aim was to evaluate the outcome of these subjects.
Methods: 210 COPD were observed from January 1991 to decembev 1995: 176 
with chronic severe hypoxemia (Pa02 50.8 £  6.5 mmHg) treated with LTOT 
(LTOT subjects) and 34 with NOD, assessed by 15% of the recorded time with 
SaOa < 90 and diurnal Pa02 64 ±  7 mmHg (NOD subjects).
Results: We compared age and FEV] of LTOT subjects and NOD subjects (Stu­
dent’s t test, level of significance p < 0,05), NOD subjects compared to LTOT 
subjects were younger (64 ±  3 vs 70 ±  0.4 yrs; p < 0.005), had FEVi higher (50 
±  2.7 vs 38.6 ±  2.7% predicted; p < 0.0001). During follow-up, daytime Pa02 
in 10/34 NOD subjects fall to values that required LTOT: these patients showed, 
compared to other 24 NOD subjects, FEVi % significantly reduced (42 ±  7 versus 
56.6 ±  2%, p <  0.0001) and greater Pack Years (58 db 15 versus 35 ±  13* p < 
0.0001) while age was not significantly different (61.3 ±  4.6 versus 64.6+/5.6). 
Conclusions: We speculate that our 34 NOD patients are a subgroup, with an 
earlier stage of their disease, leading progressively to severe chronic hypoxemia: 
bronchial obstruction and Pack Years are the risk factors for the worsening diurnal
Pa02.
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Assessment of domiciliary oxygen therapy effectiveness by means of arterial 
blood gas analysis a t  home and long-term oximetry in patients witli COPD
J.A. Lopez, M.C. Vericat, O. Parra, J.M. Guerra, J.E, Boada, L Hernandez. Sernei 
de Pneumologia, Hospital Sag rat Cor. Barcelona, Spain
Aim: 1. To assess if domiciliary oxygen therapy (DO) in COPD patients, is 
effective to reach, breathing oxygen, a resting Pa02 >  60 mm Hg and a CT<>o 
(percentage of time spent with Sp02 < 90%) while breathing oxygen <15%.
2. To assess the cause of DO failure: Malfunctioning oxygen delivery system 
(MODS), Insufficient prescribed oxygen dose (IOD), Patient’s mistake (PM), or 
Mixed reasons (MR). 3. To analyse the sensitivity of long-term home oximetry in 
detecting patients with a resting, breathing oxygen, Pa02 < 60 mm Hg.
Methods: 73 clinically stable COPD patients with chronic respiratory insufficiency, 
without other heart, pleural, lung or thorax notable pathologies that have been 
using DO for at least 1 year (55 concentrators, 8 cylinders and 10 liquid oxygen 
system) were consecutively recruited from ambulatory control of 5 Hospitals. 
Interventions and Measurements: Arterial blood gases determined at rest, breath­
ing oxygen at patients’ home and breathing room air in the hospital. Technical 
check of oxygen sources using a gas analyser and a precision rotameter. Oximetry 
recording during the oxygen therapy time, considering two differents periods: *‘day 
with oxygen (DOX)” and “sleep with oxygen (SOX)”.
Results: (1) 9 patients (12,3%) of 73 studied were excluded because they had a 
resting room air P a0 2l >60 mm Hg.
(2) 29 patients (45.3%) of 64 with a resting room air Pa02 < 60 mm Hg, were 
pooriy controlled with their DO: 13 (20.3%) showed a resting, breathing oxygen, 
Pa02 < 60 mm; 16 (25%) had a CT90 >  15% during DOX and/or SOX.
(3) 26/73 (36%) oxygen delivery systems supply flows lower or equal to 75% 
of flow indicated on their caudalimeter. 54/55 concentrators deliver oxygen with 
concentration >90%.
(4) The causes of DO failure were: MODS 6/29, IOD 14/29, PM 2/29 and MR 
7/29
(5) 12 patients of 13 with a resting breathing oxygen Pa02 < 60 mm Hg had 
a CT<jo > 15% during DOX and/or SOX. Sensitivity of oximetric recording = 
92.3%.
Conclusions: (1) The insufficient oxygen flow by MODS, IOD, PM or MR produce 
unsatisfactory control of hypoxemia in 45% of COPD patients with DO studied, 
(2) The long-term oximetry is an adequate method to evaluate the effectiveness of 
DO. It should be used systematically,
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